{"company":{"id":2087869,"name":"Vera Therapeutics","domain":"veratx.com","url":"https://alion.io/company/veratx"},"section":"news","answer":"Vera Therapeutics: 8 headlines on record, 4 headlines in the last 90 days.","figures":[{"label":"Headlines","value":"8"},{"label":"In 90 days","value":"4"},{"label":"Milestones","value":"0"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":8}],"news":[{"date":"2026-09-15","kind":"News","title":"Vera Therapeutics (VERA) Stock Surges Following Promising ORIGIN3 Trial Results","source":"Blockonomi","url":"https://blockonomi.com/vera-therapeutics-vera-stock-surges-following-promising-origin3-trial-results/"},{"date":"2026-09-15","kind":"News","title":"Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/vera-therapeutics-shares-rise-13-133746980.html"},{"date":"2026-09-15","kind":"News","title":"Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/vera-therapeutics-announces-trutakna-atacicept-vymj-stabilized-egfr-and-prevented-kidney-disease-progression-through-two-years-in-origin-3-final-efficacy-analysis-in-iga-nephropathy-1036546071"},{"date":"2026-09-05","kind":"News","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1036524165"},{"date":"2026-07-09","kind":"News","title":"Vera Therapeutics: A Crowded IgAN Market Leaves No Room For A Premium (Downgrade)","source":"seekingalpha.com","url":"https://seekingalpha.com/article/4920993-vera-therapeutics-crowded-igan-market-leaves-no-room-for-premium-downgrade"},{"date":"2026-07-08","kind":"Press release","title":"Vera Therapeutics gains FDA nod for TRUTAKNA launch","source":"The Globe and Mail","url":"https://theglobeandmail.com/investing/markets/stocks/VERA-Q/pressreleases/3189524/vera-therapeutics-gains-fda-nod-for-trutakna-launch/"},{"date":"2025-11-16","kind":"News","title":"Vera Therapeutics Submits BLA to FDA for Atacicept Fusion Protein","source":"jdsupra.com","url":"https://jdsupra.com/legalnews/vera-therapeutics-submits-bla-to-fda-9092467/"},{"date":"2024-10-28","kind":"News","title":"Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years","source":"benzinga.com","url":"https://benzinga.com/general/biotech/24/10/41577251/vera-therapeutics-atacicept-shows-sustained-substantial-improvement-in-kidney-function-for-patien"}],"as_of":"2026-11-16","cite":"Vera Therapeutics, News. Alion, Nov 16, 2026. https://alion.io/company/veratx/news","html_url":"https://alion.io/company/veratx/news","json_url":"https://alion.io/company/veratx/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-16T00:37:53Z"}}